Provided By GlobeNewswire
Last update: Jan 18, 2025
NEW YORK, Jan. 17, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that the U.S. Food and Drug Administration (FDA) has approved the MediBeacon® TGFR for the assessment of kidney function in patients with normal or impaired renal function.
Read more at globenewswire.comNYSE:VATE (7/25/2025, 8:04:00 PM)
5.81
+0.11 (+1.93%)
Find more stocks in the Stock Screener